Synonym
RO314724; RO 314724; RO314724; Ro 31-4724; Ro31-4724; Ro-31-4724.
IUPAC/Chemical Name
(2S)-ethyl 2-((2S)-2-(2-(2-(hydroxyamino)-2-oxoacetyl)-4-methylpentanamido)-4-methylpentanamido)propanoate
InChi Key
SEOSLRNQJVROOM-HPNRGHHYSA-N
InChi Code
InChI=1S/C19H33N3O7/c1-7-29-19(27)12(6)20-17(25)14(9-11(4)5)21-16(24)13(8-10(2)3)15(23)18(26)22-28/h10-14,28H,7-9H2,1-6H3,(H,20,25)(H,21,24)(H,22,26)/t12-,13?,14-/m0/s1
SMILES Code
C[C@H](NC([C@@H](NC(C(C(C(NO)=O)=O)CC(C)C)=O)CC(C)C)=O)C(OCC)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
soluble in DMSO, not soluble in water.
Shelf Life
>5 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
415.48
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Steinmeyer J, Daufeldt S, Taiwo YO. Pharmacological effect of tetracyclines on proteoglycanases from interleukin-1-treated articular cartilage. Biochem Pharmacol. 1998 Jan 1;55(1):93-100. PubMed PMID: 9413935.
2: Steinmeyer J, Daufeldt S, Kalbhen DA. Effects of the hydroxamic acid derivate Ro 31-4724 on the metabolism and morphology of interleukin-1-treated cartilage explants. Pharmacology. 1997 Aug;55(2):95-108. PubMed PMID: 9323309.
3: Newby AC, Southgate KM, Davies M. Extracellular matrix degrading metalloproteinases in the pathogenesis of arteriosclerosis. Basic Res Cardiol. 1994;89 Suppl 1:59-70. Review. PubMed PMID: 7945177.
4: Finch-Arietta M, Johnson W, Lusch L, Fotouhi N, Walsky R, Hanglow AC. Characterization of a tight-binding MMP-3 inhibitor using improved fluorescence spectroscopy techniques. Agents Actions. 1993;39 Spec No:C189-91. PubMed PMID: 8273564.
5: Southgate KM, Davies M, Booth RF, Newby AC. Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation. Biochem J. 1992 Nov 15;288 ( Pt 1):93-9. PubMed PMID: 1445285; PubMed Central PMCID: PMC1132084.
6: Nixon JS, Bottomley KM, Broadhurst MJ, Brown PA, Johnson WH, Lawton G, Marley J, Sedgwick AD, Wilkinson SE. Potent collagenase inhibitors prevent interleukin-1-induced cartilage degradation in vitro. Int J Tissue React. 1991;13(5):237-41. PubMed PMID: 1666894.
